HCM
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- HUTCHMED submits a U.S. NDA for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancerSep 29, 2026
- HUTCHMED launches a global trial of HMPL-A830, a KRAS-EGFR antibody-drug conjugate, in patients with solid tumorsSep 28, 2026
- HUTCHMED entered a licensing agreement with GSK for a KRAS-EGFR antibody-drug conjugate cancer therapySep 7, 2026
- HUTCHMED received NMPA approval for ATLED (fanregratinib) to treat FGFR2 fusion or rearrangement intrahepatic cholangiocarcinomaAug 28, 2026
- HUTCHMED reported that ORPATHYS plus TAGRISSO produced statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after TAGRISSO progressionAug 17, 2026